Pfizer Eyes Protalix Biotherapeutics After Promising Clinical Trials

Two weeks after Israeli Protalix Biotherapeutics announced the success of phase III clinical trials for a pipeline treatment for Gaucher's disease, Pfizer has shown notable interest in the firm through a preliminary meeting. While speculation mounts over a possible buy-out, we note that Pfizer are more likely to take a cautious stance, particularly since a co-operative or co-licensing deal is a more attractive option. Teva is likely to show interest in Protalix as the company's chairman holds a 9.9% stake in the smaller biopharmaceutical firm. However, at this early stage, we believe that much depends on the strength of Protalix's

To read the full article, please sign in or take a free trial.